YUGOSLAV VACCINE PROGRAM

12 April 1992

ICN Pharmaceuticals of California and ICN-Galenika are to partly finance a project costing over $100,000 to vaccinate children in the Yugoslav province of Kosovo, reports the Tanjug agency.

Also participating in the program will be the United Nations Industrial, Cultural and Educational Fund, which will supply medicines worth $10,000, the Ministry of Health of the republic of Serbia and the Swiss Poper Foundation, which will provide $35,000. Kosovo is the poorest part of Yugoslavia, and has a birth rate of 27.8 per 1,000, compared to Serbia's 10.4.

- Unless Latvia can come to an agreement on raw materials with Russia and other Commonwealth of Independent States members, its already-limited drug industry will come to a halt, say government officials. Latvia had previously relied on exports from these states, but they now have little to export, and require payment in either hard currency or food.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight